Spruce Biosciences Inc reports results for the quarter ended December 31 - Earnings Summary

• Spruce Biosciences Inc SPRB.OQ reported a quarterly adjusted loss of 57 cents​​ per share for the quarter ended December 31, lower than the same quarter last year, when the company reported EPS of -24 cents. The mean expectation of five analysts for the quarter was for a loss of 21 cents per share. Wall Street expected results to range from -25 cents to -16 cents per share.

• Revenue fell 75.9% to $697.00 thousand from a year ago; analysts expected $885.00 thousand.

• Spruce Biosciences Inc's reported EPS for the quarter was a loss of 57 cents​.

• The company reported a quarterly loss of $23.56 million.

• Spruce Biosciences Inc shares had fallen by 54.5% this quarter and lost 68.6% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts was unchanged in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy," 5 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "hold"

• Wall Street's median 12-month price target for Spruce Biosciences Inc is $1.00

This summary was machine generated from LSEG data April 16 at 07:00 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)